Literature DB >> 528361

Comparative in vitro activity of LY 127935 (6059-S), seven cephalosporins, three aminoglycosides, carbenicillin, and ticarcillin.

C Watanakunakorn, C Glotzbecker.   

Abstract

LY 127935 (6059-S), a new semi-synthetic beta-lactam antibiotic was tested simultaneously with 6 cephalosporins, 3 aminoglycosides, carbenicillin and ticarcillin against 398 clinical isolates of Gram-negative bacilli and Gram-positive cocci. Many of the organisms were selected for study because of known resistance to one or more of the clinically available antibiotics tested. Escherichia coli, Klebsiella, Serratia and Providencia were susceptible to LY 127935. Some resistant strains of Enterobacter, Proteus, Pseudomonas aeruginosa and Acinetobacter were also resistant to LY 127935, but many of the strains resistant to other antibiotics were susceptible to LY 127935. The activity of LY 127935 against Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans and Streptococcus bovis was similar to that of cephalexin and cephradine. LY 127935 was not active against methicillin-resistant S. aureus nor enterococcus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 528361     DOI: 10.7164/antibiotics.32.1019

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

Review 2.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

3.  Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.

Authors:  P C Fuchs; R N Jones; C Thornsberry; A L Barry; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

5.  Moxalactam in the therapy of serious infections.

Authors:  R L Marier; S Faro; C V Sanders; W Williams; F Derks; A Janney; K Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Cefoperazone: spectrum of antibacterial activity and disc diffusion testing.

Authors:  C Thornsberry; R N Jones
Journal:  Drugs       Date:  1981       Impact factor: 9.546

Review 7.  The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Authors:  Jonathan Turner; Alyssa Muraoka; Michael Bedenbaugh; Blaine Childress; Lauren Pernot; Mark Wiencek; Yuri K Peterson
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.